The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
ApoE-Directed Therapeutics Rapidly Clear β-Amyloid and Reverse Deficits in AD Mouse Models
Open accessAbstract
Reversing Decline?: Apolipoprotein E (apoE) normally helps in the clearance of β-amyloid from the brain, a process that is compromised in Alzheimer's disease. Cramer et al. (p. 1503 , published online 9 February; see the Perspective by Strittmatter ) now show that a drug that increases apoE expression rapidly promoted soluble β-amyloid clearance in a mouse model of Alzheimer's disease. The drug also improved cognitive, social, and olfactory performance and rapidly improved neural circuit function. Similar therapeutics may potentially help to ameliorate the symptoms of Alzheimer's disease and its prodromal states.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several groups have reported that trans-BBB efflux of Aβ into peripheral blood circulation is one of the main pathways of physiological clearance with ApoE, ApoJ, and ApoA1 as chaperones27,31,32.”
From Brain-targeted drug delivery by manipulating protein corona functions (2019) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“bexarotene (an RXR agonist) increases apoE levels”
From APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease (2012) · cites this paper as [76]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Several studies demonstrated that treatment of LXR/RXR agonists increase the levels of ABCA1 and APOE and decrease amyloid deposition in APP overexpressing cells and mice [73-77].”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [74]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, treatment of several AD Tg mice models with liver X receptor or retinoid X receptor agonists, which upregulate ApoE expression and enhance its lipidation status, resulted in reduction of Ab plaque load through enhancing clearance of Ab by glial cells.43,44”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [44]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, the RXR agonist bexarotene has been reported to facilitate the intracellular degradation of soluble A 1-42 in a PPAR␥-, liver X receptor-, and apolipoprotein E-dependent manner (Cramer et al., 2012).”
From PPARγ/RXRα-Induced and CD36-Mediated Microglial Amyloid-β Phagocytosis Results in Cognitive Improvement in Amyloid Precursor Protein/Presenilin 1 Mice (2012) · cites this paper as Cramer et al., 2012
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“apoE is a central apolipoprotein in cerebral cholesterol metabolism and is involved in brain amyloid metabolism, blood brain barrier integrity, and transport of various lipid species to neuronal cells [15][16][17][18][19].”
From APOE and vascular disease: Sequencing and genotyping in general population cohorts (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The similar findings presently observed for rare APOE variants with low apoE may reflect that the intracerebral vasculature, brain tissue and blood-brain barrier are dependent on normal levels of apoE for sufficient local lipid transport and βamyloid clearance [17,18,31,43].”
From APOE and vascular disease: Sequencing and genotyping in general population cohorts (2023) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Bexarotene is an FDA-approved liver X receptor/retinoid X receptor agonist for use in refractory cutaneous T cell lymphoma and has been shown to enhance Aβ clearance and improve cognitive performance in plaque-depositing mouse models209.”
From Multifaceted roles of APOE in Alzheimer disease (2024) · cites this paper as [209]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Still, recent findings that pharmacological induction of Apoe expression in mice ameliorates Aβ production and plaque deposition strongly supports an inverse correlation of APOE concentration with brain Aβ levels (Cramer et al., 2012).”
From The Pro-Neurotrophin Receptor Sortilin Is a Major Neuronal Apolipoprotein E Receptor for Catabolism of Amyloid-β Peptide in the Brain (2013) · cites this paper as Cramer et al., 2012
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“significantly reduces insoluble A after 3 days”
From APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease (2012) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“although plaque levels at 3 months remained unchanged (76).”
From APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease (2012) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“decreases soluble A in mice within hours”
From APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease (2012) · cites this paper as [76]
The cited source says what the claim attributes to it.
In the citing paper
“Cramer et al. demonstrated that RXR activation facilitate Aβ clearance in an ApoE dependent manner [74].”
From MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease (2016) · cites this paper as [74]
The cited source says what the claim attributes to it.
In the citing paper
“These published data indicate that the ApoE/Ab interaction may result in multidirectional effects that may promote Ab degradation by nonneuronal cells 43,44 while enhancing Ab accumulation in neurons.”
From Blocking the Interaction between Apolipoprotein E and Aβ Reduces Intraneuronal Accumulation of Aβ and Inhibits Synaptic Degeneration (2013) · cites this paper as [44]
The cited source says what the claim attributes to it.
In the citing paper
“Recently, we have shown that activation of the Retinoid X Receptor, the obligate heterodimeric partner of PPARγ and LXRs, rapidly reverses AD pathology in mouse models of AD, and many of the beneficial effects seen in that study may occur through activation of PPAR signaling pathways (Cramer et al., 2012).”
From Mechanisms Underlying the Rapid Peroxisome Proliferator-Activated Receptor-γ-Mediated Amyloid Clearance and Reversal of Cognitive Deficits in a Murine Model of Alzheimer's Disease (2012) · cites this paper as Cramer et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“In addition, several studies have demonstrated that increasing apoE lipidation, either through genetic or pharmacological approaches, promotes Aβ clearance and improves cognitive performance in mice (27, 44, 45).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [45]
The cited source says what the claim attributes to it.
In the citing paper
“This should be seen in the context that b-amyloid markers do become abnormal up to 20 years before clinical symptoms become overt [114], and because expression of apoE in the brain mediates clearance of amyloid-b peptides [89], a clearance that is impaired in Alzheimer disease [90].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, induction of murine Apoe expression improves amyloid-b clearance and cognition; this finding also underlines the importance of the level of apoE [89].”
From Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review (2016) · cites this paper as [89]
The cited source says what the claim attributes to it.
In the citing paper
“the administration of RXR or LXR agonists reduces Aβ aggregation and restores cognitive function in AD mouse model (11, 12)”
From Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Bexarotene has shown therapeutic effects in AD model mice (11)”
From Nuclear SphK2/S1P signaling is a key regulator of ApoE production and Aβ uptake in astrocytes (2024) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“In fact, increasing the levels and lipidation of apoE is a therapeutic mechanism attributed to the class of peroxisome proliferator-activated receptor-γ, retinoid × receptor, and liver × receptor agonists that have shown recent promise (Cao et al., 2007, Cramer et al., 2012, Lefterov et al., 2007, Terwel et al., 2011).”
From Apolipoprotein E–low density lipoprotein receptor interaction affects spatial memory retention and brain ApoE levels in an isoform-dependent manner (2014) · cites this paper as Cramer et al., 2012
The cited source says what the claim attributes to it.
In the citing paper
“In 2012, Cramer et al. elegantly demonstrated that oral administration of this molecule decreased the area and number of A plaques, increased the clearance of A peptides, stimulated memory (contextual fear conditioning) and olfactory functions, and improved the social behavior (construction nest) of treated AD mice [17].”
The cited source says what the claim attributes to it.
In the citing paper
“Bexarotene has been shown to induce the expression of ApoE in several CNS cell types and in brain extracts [17,63,64]”
In the citing paper
“Oral administration of the RXR agonist bexarotene in a mouse model of AD facilitated rapid clearance of soluble Aβ (103). The therapeutic effect was linked to the induction of increased levels of ApoE. Moreover, a recent study showed that bexarotene induces TREM2 expression in microglia (197).”
From Microglia Function in the Central Nervous System During Health and Neurodegeneration (2017) · cites this paper as [103]
In the citing paper
“Bexarotene has been reported to improve memory, cognition, and pathology in mouse models of AD819 and aging11 and is now in early phase clinical trials2021.”
From Neuronally-directed effects of RXR activation in a mouse model of Alzheimer’s disease (2017) · cites this paper as [8]
In the citing paper
“Bexarotene has previously been shown to reduce amyloid plaque pathology in APP/PS1, APPPS1–21, and Tg2576 mouse models of AD8.”
From Neuronally-directed effects of RXR activation in a mouse model of Alzheimer’s disease (2017) · cites this paper as [8]
In the citing paper
“Furthermore, bexarotene induces microglial and astrocyte-mediated clearance of A peptides, although the corresponding cellular and molecular mechanisms have yet to be characterized in detail [17].”
In the citing paper
“In 2012, Cramer et al. elegantly demonstrated that oral administration of this molecule decreased the area and number of A plaques, increased the clearance of A peptides, stimulated memory (contextual fear conditioning) and olfactory functions, and improved the social behavior (construction nest) of treated AD mice [17].”
In the citing paper
“In 2012, Cramer et al. elegantly demonstrated that oral administration of this molecule decreased the area and number of A plaques, increased the clearance of A peptides, stimulated memory (contextual fear conditioning) and olfactory functions, and improved the social behavior (construction nest) of treated AD mice [17].”
In the citing paper
“In 2012, Cramer et al. elegantly demonstrated that oral administration of this molecule decreased the area and number of A plaques, increased the clearance of A peptides, stimulated memory (contextual fear conditioning) and olfactory functions, and improved the social behavior (construction nest) of treated AD mice [17].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Analyzing real-time PCR data by the comparative CT method
Schmittgen, T. D., & Livak, K. J. (2008) · Nature Protocols · doi:10.1038/nprot.2008.73 · Cited by 26,190
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice
Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210
Decreased Clearance of CNS β-Amyloid in Alzheimer’s Disease
Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., Yarasheski, K. E., & Bateman, R. J. (2010) · Science · doi:10.1126/science.1197623 · Cited by 2,078
Initiative, T. A. D. N., Hollingworth, P., CHARGE consortium, EADI1 consortium, Harold, D., Sims, R., Gerrish, A., Lambert, J.-C., Carrasquillo, M. M., Abraham, R., et al. (2011) · Nature Genetics · doi:10.1038/ng.803 · Cited by 1,997
Naj, A. C., Jun, G., Beecham, G. W., Wang, L.-S., Vardarajan, B. N., Buros, J., Gallins, P. J., Buxbaum, J. D., Jarvik, G. P., Crane, P. K., et al. (2011) · Nature Genetics · doi:10.1038/ng.801 · Cited by 1,901
Amyloid-β–induced neuronal dysfunction in Alzheimer's disease: from synapses toward neural networks
Palop, J. J., & Mucke, L. (2010) · Nature Neuroscience · doi:10.1038/nn.2583 · Cited by 1,651
A PPARγ-LXR-ABCA1 Pathway in Macrophages Is Involved in Cholesterol Efflux and Atherogenesis
Chawla, A., Boisvert, W. A., Lee, C.-H., Laffitte, B. A., Barak, Y., Joseph, S. B., Liao, D., Nagy, L., Edwards, P. A., Curtiss, L. K., et al. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00164-2 · Cited by 1,347
Self-citationGamma rhythms and beta rhythms have different synchronization properties
Kopell, N., Ermentrout, G. B., Whittington, M. A., & Traub, R. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.4.1867 · Cited by 1,072
Aβ42‐driven cerebral amyloidosis in transgenic mice reveals early and robust pathology
Radde, R., Bolmont, T., Kaeser, S. A., Coomaraswamy, J., Lindau, D., Stoltze, L., Calhoun, M. E., Jäggi, F., Wolburg, H., Gengler, S., et al. (2006) · The EMBO Reports · doi:10.1038/sj.embor.7400784 · Cited by 986
Flagged first, then by citations
1 of the 31 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
Self-citationApolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Microglia Function in the Central Nervous System During Health and Neurodegeneration
Colonna, M., & Butovsky, O. (2017) · Annual Review of Immunology · doi:10.1146/annurev-immunol-051116-052358 · Cited by 2,894
Immune attack: the role of inflammation in Alzheimer disease
Heppner, F. L., Ransohoff, R. M., & Becher, B. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn3880 · Cited by 2,134
Neuroinflammation and M2 Microglia: The Good, the Bad, and the Inflamed
Cherry, J. D., Olschowka, J. A., & O’Banion, M. K. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-98 · Cited by 1,748
Metadata
- Authors
- Cramer, P. E., Cirrito, J. R., Wesson, D. W., Lee, C. Y. D., Karlo, J. C., Zinn, A. E., Casali, B. T., Restivo, J. L., Goebel, W. D., James, M. J., Brunden, K. R., Wilson, D. A., & Landreth, G. E.
- Affiliations
- Case Western Reserve University (US)
- Washington University in St. Louis (US)
- Nathan Kline Institute for Psychiatric Research (US)
- University of Pennsylvania (US)
- Corresponding author
- Landreth, Gary E.
- ORCID
- Venue
- Science
- Published
- 2012-03-23
- Volume
- 335
- Issue
- 6075
- Pages
- 1503-1506
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC3651582
- OpenAlex
- W2081388499
- Cited by
- 1,050
- References
- 31
- Citations by year
- 2026: 27 · 2025: 31 · 2024: 41 · 2023: 37 · 2022: 53 · 2021: 67 · 2020: 59 · 2019: 71 · 2018: 57 · 2017: 68 · 2016: 90 · 2015: 106 · 2014: 131 · 2013: 123 · 2012: 88
- FWCI
- 96.72
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (R01AG037693, AG030482-03S1, R01AG030482, K01AG029524, P50AG005681)
- National Institute on Deafness and Other Communication Disorders (DC-003906, R01DC003906)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Keywords
- Alzheimer's disease, amyloid-beta clearance, apolipoprotein E, bexarotene, retinoid X receptor, PPARγ, liver X receptor, nuclear receptor agonists, amyloid plaques, cognitive impairment, social dysfunction, olfactory dysfunction, neural circuit function
- MeSH terms
- Liver X Receptors, Bexarotene, Alzheimer Disease, Amyloidosis, Animals, Apolipoproteins E, Astrocytes, Behavior, Animal, Brain, Disease Models, Animal, Male, Mice, Inbred C57BL, Mice, Transgenic, Odorants, Olfactory Pathways, Phagocytosis, Tetrahydronaphthalenes, Amyloid beta-Peptides, Microglia, Extracellular Fluid, Retinoid X Receptors, PPAR gamma, Mice, Orphan Nuclear Receptors, Plaque, Amyloid, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
